Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 43,947

Document Document Title
WO/2021/069927A1
The disclosures herein relate to novel compounds of formula (1): (1) and salts thereof, wherein A, X, R1, R2, R3, R4, R10 and R11 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk o...  
WO/2020/063696A8
Provided are a preparation of a semicarbazide-sensitive amine oxidase inhibitor and the use thereof. In particular, dislosed are a compound as shown in formula I, or a stereoisomer or racemate or pharmaceutically acceptable salt thereof....  
WO/2021/069339A1
The present invention relates to homopiperazinyl and homopiperidinyl quinazolin- 4(3H)-one derivatives having dual pharmacological activity towards both the α2δ subunit of the voltage-gated calcium channel and the sigma-1 (σ1) recepto...  
WO/2021/068698A1
Disclosed are compounds inhibiting the conversion of α–KG to D-2-HG, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmac...  
WO/2021/072232A1
The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.  
WO/2021/068755A1
Disclosed in the present invention are a compound having a BRD4 inhibitory activity, a preparation method therefor and the use thereof. The structure of the compound having the BRD4 inhibitory activity of the present invention is as show...  
WO/2021/012049A8
Disclosed are compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein — is a single bond, and each Y is N or CR4; or — is absent, and each Y is NRY, carbonyl, or C(RY)2, wherein each R1 is H or optionally subst...  
WO/2021/071919A1
The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided ...  
WO/2021/068773A1
The present invention relates a group of tetrahydroindoloquinazoline compounds and the use thereof, wherein the structure of the tetrahydroindoloquinazoline compounds is as shown in general formula (I). The tetrahydroindoloquinazoline co...  
WO/2021/070054A1
Compounds and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.  
WO/2021/070132A1
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: Formula I wherein R1, R2, R3,...  
WO/2021/068898A1
The present invention pertains to the field of medicinal chemistry, and relates to a novel KRAS G12C protein inhibitor, a preparation method therefor, and a use thereof. Specifically, a compound with a structure of formula (I) is provide...  
WO/2021/068953A1
The present invention belongs to the field of medicinal chemistry and relates to a class of substituted tricyclic compounds as PRMT5 inhibitors and the use thereof. Specifically, the present invention provides a compound represented by f...  
WO/2021/063404A1
A biaryl compound. Specifically disclosed is a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.  
WO/2021/066088A1
Provided is a compound represented by the following formula (1) and a pharmacologically acceptable salt, which have a regulatory activity for a histamine H4 receptor and are useful for the treatment and/or prevention of diseases or condi...  
WO/2021/063276A1
The present invention relates to a macrocyclic derivative, a preparation method therefor and use thereof in medicine. In particular, the present invention relates to a macrocyclic derivative as represented by general formula (I), a prepa...  
WO/2021/063915A1
The present invention relates to the following compounds (I) wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis (e.g. in com...  
WO/2021/064569A1
The present invention relates to novel, selective, radiolabelled compound having monoacylglycerol lipase (MGL) affinity which are useful for imaging and quantifying MGL receptor expression, distribution and enzyme occupancy in tissues, u...  
WO/2021/067805A1
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...  
WO/2021/067772A1
Formulations of Compound 1 or a pharmaceutically acceptable salt thereof are described. Also disclosed are capsules having a dry blended powder comprising Compound 1 or a pharmaceutically acceptable salt thereof. The Compound 1 or a phar...  
WO/2021/065898A1
Provided are: an azepan derivative represented by general formula (I) and a pharmaceutically acceptable salt thereof (in the formula: R1 represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R2 and R3 are the...  
WO/2021/066873A1
The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1 Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a ...  
WO/2021/066123A1
Provided is a novel metal complex which can be used as an electron transporting material. Metal complexes respectively represented by formulae (1) to (3). RA1 to RA9, RC1 to RC8 and RE1 to RE6 independently represent a single bond, an al...  
WO/2021/064142A1
The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof : formula (I) and to pharmac...  
WO/2021/067326A1
Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein X, Y, A, G, R1, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9,...  
WO/2020/055858A8
Provided herein are compounds that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza. (I)  
WO/2021/067569A1
Disclosed are compounds having structural formula I, and related salts and pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating diseases and conditions such as kidney disease, kidney failure, kidney ston...  
WO/2021/067967A1
The present invention relates to pyrazolo[3,4-b]pyridine compounds. The present invention further relates to methods for inhibiting Plasmodium comprising contacting Plasmodium with pyrazolo[3,4-b]pyridine compounds described herein. Also...  
WO/2021/067657A1
Disclosed are compounds of Formula (I) or salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, 8, or 9, and pharmace...  
WO/2021/064141A1
The present invention relates to compounds of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof (I), in particular for use in...  
WO/2021/067827A1
The present disclosure provides compounds, such as compounds of Formula I, and compositions that are MCL1 inhibitors.  
WO/2021/067670A1
The present disclosure provides a method of preparing a compound represented by formula (I). The method comprises reacting in a reaction mixture a first starting material represented by formula (II) and a second starting material represe...  
WO/2021/062491A1
Cibalackrot red dye monomer and dimer compounds of formulae (I) and (II) are disclosed as well as combination of the Cibalackrots with host matrices such as a mixed host of mCP and HBT. Use of the Cibalackrots as laser dyes as well in or...  
WO/2021/067606A1
The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand...  
WO/2021/067217A1
The present disclosure is directed to compounds of Formula (I): which modulate PD-1/PD-L1 protein/protein interaction, compositions, and methods of treating various diseases, including infectious diseases and cancer.  
WO/2021/067791A1
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...  
WO/2021/063914A1
The present invention relates to the following compounds (I) wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis (e.g. in com...  
WO/2021/063332A1
The present invention relates to use of an EZH2 inhibitor combined with a CDK4/6 inhibitor in the preparation of a drug for treating a tumor. Specifically, the EZH2 inhibitor involved in the present invention is selected from a compound ...  
WO/2021/064571A1
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth Formula I.  
WO/2021/060453A1
The present invention pertains to a compound represented by formula (1a) [in the formula: p represents 1 or 2; R1 to R4 represent a hydrogen atom, etc.; ring A represents a cycloalkylene, etc.; L represents a single bond, etc.; and R rep...  
WO/2021/062307A1
The disclosure provides methods for the for treatment of psychosis, such as schizophrenia, or depression (such as bipolar depression) and/or anxiety, comprising administering to a patient in need thereof, (i) a 5-HT2A or 5-HT2A/D2 recept...  
WO/2021/057970A1
The present invention relates to a RET inhibitor, a pharmaceutical composition thereof and use thereof in the pharmaceutical field. Specifically, the present invention relates to a compound represented by formula (I), or a stereoisomer, ...  
WO/2021/061053A1
There are provided new heterobifunctional agents designed to mediated formation of protein-protein dimers and promote ubiqutination of a protein of the dimer. Also provided are methods of synthesizing the agents, pharmaceutical formulati...  
WO/2021/057890A1
A class of compounds that have a pyrazine structure, specifically disclosed is a compound represented by formula (VII), isomers or pharmaceutically acceptable salts thereof, and an application thereof in the preparation of CRAC inhibitors.  
WO/2021/041539A3
This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.  
WO/2021/061898A1
The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for trea...  
WO/2021/059086A1
Provided is a novel organic compound. Provided is an organic compound represented by general formula (G1). (In general formula (G1), either A or B is a group represented by the general formula (g1). Furthermore, the other of A and B, R1...  
WO/2021/057998A1
The present disclosure relates to a preparation method for a pyrroloaminopyridazinone compound. Specifically, the present disclosure relates to a method for preparing a compound represented by formula (III), comprising the step of reacti...  
WO/2021/060307A1
The present invention addresses the problem of providing an imidazopyridine compound having FGFR inhibitory activity or a salt thereof, and a pharmaceutical composition. The present invention provides an imidazopyridine compound represen...  
WO/2021/058017A1
Provided herein are novel bifunctional compounds formed by conjugating AR antagonist moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 Ubiquitin ligase for degradation, and methods of preparation ...  

Matches 1 - 50 out of 43,947